Company
Management team:
Chief Executive Officer: Prof CHAN Chi Wai Michael
Chief Operating Officer: Prof POON Lit Man Leo
Senior Advisor: Prof PEIRIS Joseph Sriyal Malik
R&D team:
Chief Scientific Officer: Prof HUI Pui Yan Kenrie
Chief Technical Officer: Dr CHING Hiu Ha Rachel
R&D executive: Dr LI Tak Ho Alex
Technical Officer: Miss HO Wing Chi Taylor
Honorary Pathologist: Prof NICHOLLS John Malcolm
Honorary Business Development Advisor: Dr HO Chi Yung Alfred
Clinical and Overseas Advisors:
Prof TAM KH Paul KH - Vice President, Macau University of Science and Technology
Prof HO CM James - Clinical Associate Professor, at the Department of Medicine, School of Clinical Medicine, HKU
Prof LAU Yu-lung - Chair Professor, Department of Paediatrics and Adolescent Medicine, School of Clinical Medicine
Prof MATTHAY Michael - Professor, School of Medicine University of California
Prof KIM F Carla - Professor, Harvard Medical School, Harvard University
Description
Respiratory diseases, including Acute Lung Injury, Acute Respiratory Distress Syndrome, and chronic conditions like Asthma and Chronic Obstructive Pulmonary Disease, present significant global health challenges. These conditions, exacerbated by viral infections such as H5N1, SARS, MERS, and SARS-CoV-2, lead to high morbidity and mortality rates, severely impacting quality of life and straining healthcare systems.
C2iTech Limited, a spin-off from a prestigious academic institution, is dedicated to transforming respiratory health through innovative technologies. We specialise in personalised organoid cultivation and offer a comprehensive range of services, including organoid cryopreservation, novel respiratory drug screening, and extensive respiratory virus research. Our unique organoid platform enables the standardisation and development of tailored culture media and frozen organoid products.
Our mission is to revolutionize healthcare by addressing unmet medical needs with cutting-edge solutions. By leveraging our scientific expertise and advanced technologies, we aim to improve patient outcomes and enhance the effectiveness of respiratory health interventions.
Technology
C2iTech specialises in cultivating personalised respiratory organoids from non-invasive patient samples. These organoids act as "mini-models" of the respiratory system, enabling:
- Prediction of responses to infections and treatments
- Evaluation of therapy effectiveness
- Assessment of immune defences against respiratory diseases
Our organoids can be cryogenically stored for long-term use, creating a renewable resource for personalised medicine and advancing medical research. With a high success rate in non-invasive sampling, our organoids are invaluable for infectious disease studies and targeted therapeutic development.
2. Novel Respiratory Drug Screening
Our Novel Respiratory Drug Screening service allows pharmaceutical and biotech firms to test drugs and vaccines using organoids that closely mimic human respiratory tissues. This offers more accurate results, accelerating the development of life-saving treatments.
3. Respiratory Virus Research Service
C2iTech provides stable ex vivo research models for government agencies and academic institutions studying respiratory viruses. Our customisable models, derived from diverse donor sources, enable research into viral transmission, pathogenesis, and treatment approaches in relevant human tissue contexts.
Future R&D: Organoid Culture Development and Standardisation
We are developing a proprietary culture medium, Culture Medium 1.0, to enhance organoid growth and functionality. This innovation will optimise experimental models for applications ranging from drug testing to disease modelling.
Organoid Platform Standardisation
C2iTech is dedicated to the standardisation of organoid platforms, a critical step toward enhancing the reliability and translatability of organoid models in preclinical research. By partnering with industry leaders such as JingKe Biotech, we aim to establish comprehensive standard operating procedures (SOPs) for organoid cultivation. This initiative will not only ensure uniformity in organoid production but also facilitate the integration of these models into various therapeutic research applications.
The standardisation process will encompass the development of protocols that cover all aspects of organoid culture, including cell sourcing, media formulation, growth conditions, and characterisation methods. By implementing these SOPs, we will create a framework that allows researchers to replicate results across different labs and studies, thereby improving the quality of data generated from organoid models.
Furthermore, our initiative will prepare the organoid platform for preclinical evaluation, ensuring that these models meet regulatory requirements and are suitable for clinical translation. This preparation is vital for fostering collaboration with pharmaceutical companies and research institutions, thereby enhancing the overall impact of organoid technology in drug discovery and personalised medicine.
Consultancy & Training Services
C2iTech offers scientific consultancy and training workshops in organoid research, equipping participants with hands-on experience and industry-recognised credentials to meet the growing demand for personalised healthcare.
